Figure 1From: Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes*P < 0.05, HOX versus DOX, HOX versus medium if present; **P < 0.05, HOX versus DOX, HOX versus medium, HOX versus HDFTr.Back to article page